28.35
0.44 (1.58%)
| Penutupan Terdahulu | 27.91 |
| Buka | 27.99 |
| Jumlah Dagangan | 515,874 |
| Purata Dagangan (3B) | 2,778,573 |
| Modal Pasaran | 1,542,219,776 |
| Harga / Jualan (P/S) | 124.43 |
| Harga / Buku (P/B) | 6.04 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 19 Mar 2026 |
| Margin Operasi (TTM) | -329.90% |
| EPS Cair (TTM) | -1.37 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -7.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.98% |
| Nisbah Semasa (MRQ) | 6.55 |
| Aliran Tunai Operasi (OCF TTM) | -45.16 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -28.17 M |
| Pulangan Atas Aset (ROA TTM) | -35.24% |
| Pulangan Atas Ekuiti (ROE TTM) | -75.39% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Capricor Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -2.5 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.30 |
|
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 16.80% |
| % Dimiliki oleh Institusi | 41.06% |
| Julat 52 Minggu | ||
| Median | 60.00 (111.64%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 10 Mar 2026 | 60.00 (111.64%) | Beli | 33.40 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| BERGMANN ANTHONY | - | 30.40 | -25,000 | -760,000 |
| KRASNEY KAREN | - | 30.40 | -25,000 | -760,000 |
| SABAR KARIMAH ES | - | 30.26 | -115,000 | -3,480,954 |
| Jumlah Keseluruhan Kuantiti Bersih | -165,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -5,000,954 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 30.33 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| SABAR KARIMAH ES | Pengarah | 01 Apr 2026 | Jual automatik (-) | 53,735 | 30.12 | 1,618,498 |
| SABAR KARIMAH ES | Pengarah | 01 Apr 2026 | Pelaksanaan pilihan | 53,735 | - | - |
| BERGMANN ANTHONY | Pegawai | 31 Mar 2026 | Jual automatik (-) | 25,000 | 30.40 | 760,000 |
| BERGMANN ANTHONY | Pegawai | 31 Mar 2026 | Pelaksanaan pilihan | 25,000 | - | - |
| KRASNEY KAREN | Pegawai | 31 Mar 2026 | Jual automatik (-) | 25,000 | 30.40 | 760,000 |
| KRASNEY KAREN | Pegawai | 31 Mar 2026 | Pelaksanaan pilihan | 25,000 | - | - |
| SABAR KARIMAH ES | Pengarah | 31 Mar 2026 | Jual automatik (-) | 61,265 | 30.40 | 1,862,456 |
| SABAR KARIMAH ES | Pengarah | 31 Mar 2026 | Pelaksanaan pilihan | 61,265 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 20 Jan 2026 | Pengumuman | Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |